C12N 2795/10311
Siphoviridae
C12N2795/10311 (Siphoviridae) appears on 209 US grants and 275 published applications in this corpus.
Search patents in C12N- Granted patents
- 209
- Published applications
- 275
- Assignees
- 159
- Inventors
- 501
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 10 | 0 |
| 1998 | 7 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 8 | 3 |
| 2002 | 5 | 6 |
| 2003 | 1 | 5 |
| 2004 | 4 | 3 |
| 2005 | 2 | 3 |
| 2006 | 1 | 3 |
| 2007 | 1 | 4 |
| 2008 | 1 | 3 |
| 2009 | 1 | 2 |
| 2010 | 3 | 5 |
| 2011 | 1 | 8 |
| 2012 | 5 | 6 |
| 2013 | 4 | 10 |
| 2014 | 6 | 11 |
| 2015 | 5 | 10 |
| 2016 | 5 | 15 |
| 2017 | 11 | 10 |
| 2018 | 8 | 8 |
| 2019 | 11 | 13 |
| 2020 | 10 | 22 |
| 2021 | 9 | 30 |
| 2022 | 20 | 31 |
| 2023 | 16 | 16 |
| 2024 | 18 | 23 |
| 2025 | 17 | 11 |
| 2026 | 3 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2795/10322New viral proteins or individual genes, new structural or functional aspects ofIndexing code87
- C12N 2795/10321Viruses as suchIndexing code72
- C12N 2795/10341Use of virus, viral particle or viral elements as a vectorIndexing code70
- C12N 2795/10332Use of virus as therapeutic agent, other than vaccineIndexing code65
- C12N 2795/10331Uses of virus other than therapeutic or vaccineIndexing code33
- C12N 2795/10351Methods of production or purification of viral materialIndexing code23
- C12N 2795/10371Demonstrated in vivo effectIndexing code19
- C12N 2795/10361Methods of inactivation or attenuationIndexing code13
Recent patents
- Bacteriophages for treatment of tuberculosis31 Mar 2026US 12,589,127 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions comprising Propionibacterium acnes bacteriophages for treating acne17 Mar 2026US 12,576,024 B2Phi Therapeutics, Inc.
- Bacteriophages for the treatment of tuberculosis17 Mar 2026US 12,576,118 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Use of specific phages for the treatment of nontuberculosis mycobacteria (NTM) infections4 Nov 2025US 12,458,673 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Phage-derived particles for in situ delivery of DNA payload into C. acnes population4 Nov 2025US 12,460,216 B2Eligo Bioscience
- Bacteriophages as a tool to manipulate gut commensal immune-modulation activity17 Sep 2026US 2026/0273002 A1Technion Research & Development Foundation Limited
- Enzymes capable of mediating large-fragment dna integration into mammalian genomes and uses thereof27 Aug 2026US 2026/0250718 A1Yoltech Therapeutics Co., Ltd
- Cutibacterium acnes recombinant phages, method of production and uses thereof6 Aug 2026US 2026/0226484 A1Eligo Bioscience
- Disposable personal care products composed of nonwoven fabrics coated with bacteriophages to prevent and reduce bacterially caused skin problems9 Jul 2026US 2026/0191922 A1Parallel Health, Inc.
- Staphylococcus phage compositions and cocktails thereof7 May 2026US 2026/0124259 A1Locus Biosciences, Inc.
Most cited
By later US patents
- Generation and selection of novel DNA-binding proteins and polypeptides293US 5,096,815 AProtein Engineering Corporation · 1992
- Generation and selection of novel DNA-binding proteins and polypeptides254US 5,198,346 AProtein Engineering Corporation · 1993
- Preservation of viruses124US 5,149,653 AQuadrant Bioresources Limited · 1992
- Method of inactivation of viral and bacterial blood contaminants114US 5,418,130 ACryopharm Corporation · 1995
- Viruses with recombinant surface proteins96US 4,593,002 AThe Salk Institute Biotechnology/Industrial Associates, Inc. · 1986